Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report

Arturo Ciccullo, F. R. Ponziani, E. Maiolo, F. Pallavicini, M. Pompili

Research output: Contribution to journalArticle

Abstract

Background: Hepatitis B virus (HBV) reactivation is commonly observed in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Recent guidelines recommend antiviral prophylaxis to be continued for up to 12 months after the discontinuation of the anticancer regimen. Case Presentation: We report a case of a patient who underwent antiviral prophylaxis for 26 months after the discontinuation of a rituximab-containing chemotherapy regimen for a lymphoma and was admitted in the infectious diseases department with a 3-day history of jaundice, itching, and dark urine. After excluding other possible causes of acute liver damage, HBV reactivation was suspected. HBV-DNA was 4497000 IU/mL. Following reintroduction of entecavir, we observed a steady decline of ALT, AST, bilirubin and HBV-DNA serum levels, with a rapid resolution of acute hepatitis and an improvement in clinical conditions; one year after the event of HBV reactivation and beginning of antiviral therapy, the patient was virologically suppressed. Discussion: Our study demonstrates that the risk of HBV reactivation in HBsAg-positive patients with undetectable HBV-DNA can occur even after three years from the last administration of rituximab and several months after the withdrawal of prophylactic antiviral therapy in patients with hematological malignancies. This implies that a close monitoring of HBV-related markers including HBV-DNA must continue after the withdrawal of prophylactic NA therapy.

Original languageEnglish
JournalInfection
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Mantle-Cell Lymphoma
Hepatitis B virus
Drug Therapy
Antiviral Agents
DNA
Hepatitis B Surface Antigens
Rituximab
Hematologic Neoplasms
Pruritus
Immunosuppressive Agents
Jaundice
Bilirubin
Hepatitis
Communicable Diseases
Lymphoma
Therapeutics
Urine
Guidelines

Keywords

  • Entecavir
  • Hepatitis B
  • Lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma : a case report. / Ciccullo, Arturo; Ponziani, F. R.; Maiolo, E.; Pallavicini, F.; Pompili, M.

In: Infection, 01.01.2018.

Research output: Contribution to journalArticle

@article{b64827a203d544198213b9bd8bf6b950,
title = "Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report",
abstract = "Background: Hepatitis B virus (HBV) reactivation is commonly observed in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Recent guidelines recommend antiviral prophylaxis to be continued for up to 12 months after the discontinuation of the anticancer regimen. Case Presentation: We report a case of a patient who underwent antiviral prophylaxis for 26 months after the discontinuation of a rituximab-containing chemotherapy regimen for a lymphoma and was admitted in the infectious diseases department with a 3-day history of jaundice, itching, and dark urine. After excluding other possible causes of acute liver damage, HBV reactivation was suspected. HBV-DNA was 4497000 IU/mL. Following reintroduction of entecavir, we observed a steady decline of ALT, AST, bilirubin and HBV-DNA serum levels, with a rapid resolution of acute hepatitis and an improvement in clinical conditions; one year after the event of HBV reactivation and beginning of antiviral therapy, the patient was virologically suppressed. Discussion: Our study demonstrates that the risk of HBV reactivation in HBsAg-positive patients with undetectable HBV-DNA can occur even after three years from the last administration of rituximab and several months after the withdrawal of prophylactic antiviral therapy in patients with hematological malignancies. This implies that a close monitoring of HBV-related markers including HBV-DNA must continue after the withdrawal of prophylactic NA therapy.",
keywords = "Entecavir, Hepatitis B, Lymphoma, Rituximab",
author = "Arturo Ciccullo and Ponziani, {F. R.} and E. Maiolo and F. Pallavicini and M. Pompili",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s15010-018-1242-1",
language = "English",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel GmbH",

}

TY - JOUR

T1 - Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma

T2 - a case report

AU - Ciccullo, Arturo

AU - Ponziani, F. R.

AU - Maiolo, E.

AU - Pallavicini, F.

AU - Pompili, M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Hepatitis B virus (HBV) reactivation is commonly observed in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Recent guidelines recommend antiviral prophylaxis to be continued for up to 12 months after the discontinuation of the anticancer regimen. Case Presentation: We report a case of a patient who underwent antiviral prophylaxis for 26 months after the discontinuation of a rituximab-containing chemotherapy regimen for a lymphoma and was admitted in the infectious diseases department with a 3-day history of jaundice, itching, and dark urine. After excluding other possible causes of acute liver damage, HBV reactivation was suspected. HBV-DNA was 4497000 IU/mL. Following reintroduction of entecavir, we observed a steady decline of ALT, AST, bilirubin and HBV-DNA serum levels, with a rapid resolution of acute hepatitis and an improvement in clinical conditions; one year after the event of HBV reactivation and beginning of antiviral therapy, the patient was virologically suppressed. Discussion: Our study demonstrates that the risk of HBV reactivation in HBsAg-positive patients with undetectable HBV-DNA can occur even after three years from the last administration of rituximab and several months after the withdrawal of prophylactic antiviral therapy in patients with hematological malignancies. This implies that a close monitoring of HBV-related markers including HBV-DNA must continue after the withdrawal of prophylactic NA therapy.

AB - Background: Hepatitis B virus (HBV) reactivation is commonly observed in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Recent guidelines recommend antiviral prophylaxis to be continued for up to 12 months after the discontinuation of the anticancer regimen. Case Presentation: We report a case of a patient who underwent antiviral prophylaxis for 26 months after the discontinuation of a rituximab-containing chemotherapy regimen for a lymphoma and was admitted in the infectious diseases department with a 3-day history of jaundice, itching, and dark urine. After excluding other possible causes of acute liver damage, HBV reactivation was suspected. HBV-DNA was 4497000 IU/mL. Following reintroduction of entecavir, we observed a steady decline of ALT, AST, bilirubin and HBV-DNA serum levels, with a rapid resolution of acute hepatitis and an improvement in clinical conditions; one year after the event of HBV reactivation and beginning of antiviral therapy, the patient was virologically suppressed. Discussion: Our study demonstrates that the risk of HBV reactivation in HBsAg-positive patients with undetectable HBV-DNA can occur even after three years from the last administration of rituximab and several months after the withdrawal of prophylactic antiviral therapy in patients with hematological malignancies. This implies that a close monitoring of HBV-related markers including HBV-DNA must continue after the withdrawal of prophylactic NA therapy.

KW - Entecavir

KW - Hepatitis B

KW - Lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85055871683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055871683&partnerID=8YFLogxK

U2 - 10.1007/s15010-018-1242-1

DO - 10.1007/s15010-018-1242-1

M3 - Article

AN - SCOPUS:85055871683

JO - Infection

JF - Infection

SN - 0300-8126

ER -